Application of Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma
Open Access
- 28 May 2013
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 14 (6), 11402-11423
- https://doi.org/10.3390/ijms140611402
Abstract
Monoclonal antibody G250 (mAbG250) recognizes a determinant on carbonic anhydrase IX (CAIX). CAIX is expressed by virtually all renal cell carcinomas of the clear cell type (ccRCC), but expression in normal tissues is restricted. The homogeneous CAIX expression in ccRCC and excellent targeting capability of mAbG250 in animal models led to the initiation of the clinical evaluation of mAbG250 in (metastatic) RCC (mRCC) patients. Clinical studies confirmed the outstanding targeting ability of mAbG250 and cG250 PET imaging, as diagnostic modality holds great promise for the future, both in detecting localized and advanced disease. Confirmation of the results obtained in the non-randomized clinical trials with unmodified cG250 is needed to substantiate the value of cG250 treatment in mRCC. cG250-Based radio immuno-therapy (RIT) holds promise for treatment of patients with small-volume disease, and adjuvant treatment with unmodified cG250 may be of value in selected cases. In the upcoming years, ongoing clinical trials should provide evidence for these assumptions. Lastly, whether cG250-based RIT can be combined with tyrosine kinase inhibitors, which constitutes the current standard treatment for mRCC, needs to be established.Keywords
This publication has 69 references indexed in Scilit:
- Dosimetric Analysis of 177Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on 111In-cG250 ImagingJournal of Nuclear Medicine, 2011
- Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IXEuropean Journal of Pharmacology, 2011
- Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall SurvivalJournal of Clinical Oncology, 2010
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2010
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Signalling hypoxia by HIF hydroxylasesBiochemical and Biophysical Research Communications, 2005
- Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal CancerClinical Cancer Research, 2005
- Interferons Can Upregulate the Expression of the Tumor Associated Antigen G250-MN/CA IX, a Potential Target for (Radio)Immunotherapy of Renal Cell CarcinomaCancer Biotherapy & Radiopharmaceuticals, 2003
- Tumor Retention of 186Re-MAG3, 111In-DTPA and 125I Labeled Monoclonal Antibody G250 in Nude Mice with Renal Cell Carcinoma XenograftsCancer Biotherapy & Radiopharmaceuticals, 1998
- Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal‐cell carcinoma xenografts: Relative effects of size and affinityInternational Journal of Cancer, 1991